IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell-inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell-inflamed GEP contained IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell-inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defects associated with this pathway and its downstream effectors have shown both negative and positive correlations with response to ICB, suggesting a dual role for this pathway in tumor immunity (Ayers et al., 2017; Gao et al., 2016).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Interferon (IFN) signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays a prominent role in tumor immunity.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“In the clinic, a strong IFN-γ signature has been identified as a useful predictor and indicator of response in anti-PD-1-treated patients across various cancer indications (75,92,93).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [93]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“org Volume 127 Number 8 August 2017 Introduction Cancer cells have the ability to adapt to and avoid host immune checkpoints and surveillance as a means to promote their continued survival (1, 2).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“These data extend the observations of previous reports showing that CD8+ T lymphocytes and T cell active chemokines and T cell counterinhibitory molecules such as PD-1/PD-L1 and IDO1 are coregulated within tumors (4, 15, 21, 22) and confirm that response to anti–PD-1 blockade occurs primarily in patients with such a p…”
ResultSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Newer genomic technologies can be used to evaluate complexities of tumor and Recently, increased PD-L1 expression on the surface of tumor cells has been identified as an important determinant of response to immune therapies targeting the PD-1 axis (16).”
BackgroundSelf-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“Likewise, these data provide a much higher level of statistical validation across multiple tumor types than has previously been reported for single genes associated with the IFN-γ signaling pathway and response to PD-1 blockade (17), indicating that integrated multigene signatures might represent more robust predictiv…”
Background
Cited by
Items 701–800 of 1,011
Papadopoulos, K. P., Autio, K. A., Golan, T., Dobrenkov, K., Chartash, E., Chen, Q., Wnek, R., & Long, G. V. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2886 · Cited by 64
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Armengol, M., Santos, J. C., Fernández-Serrano, M., Profitós-Pelejà, N., Ribeiro, M. L., & Roué, G. (2021) · Cancers · doi:10.3390/cancers13020214 · Cited by 65
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Veeramachaneni, R., Yu, W., Newton, J. M., Kemnade, J. O., Skinner, H. D., Sikora, A. G., & Sandulache, V. C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002773 · Cited by 64
Jeong, S., Park, E., Kim, H.-D., Sung, E., Kim, H., Jeon, J., Kim, Y., Jung, U.-J., Son, Y.-G., Hong, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002428 · Cited by 58
Molecular predictors of response to pembrolizumab in thymic carcinoma
He, Y., Ramesh, A., Gusev, Y., Bhuvaneshwar, K., & Giaccone, G. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100392 · Cited by 67
Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength
Elliot, T. A. E., Jennings, E. K., Lecky, D. A. J., Thawait, N., Flores‐Langarica, A., Copland, A., Maslowski, K. M., Wraith, D. C., & Bending, D. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.020 · Cited by 64
CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors
Qin, V. M., Haynes, N. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.813832 · Cited by 69
Su, G.-H., Xiao, Y., Jiang, L., Zheng, R., Wang, H., Chen, Y., Gu, Y., You, C., & Shao, Z.-M. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03688-x · Cited by 69
Immunotherapy-related biomarkers: Confirmations and uncertainties
Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 71
Shen, J., Choi, Y., Lee, T., Kim, H., Chae, Y. K., Dulken, B. W., Bogdan, S., Huang, M., Fisher, G. A., Park, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008339 · Cited by 67
Rodon, J. A., Rodríguez, E., Maitland, M. L., Tsai, F. Y.-C., Socinski, M. A., Berlin, J. D., Thomas, J. S., Baghdadi, T. A., Wang, I. ‐., Guo, C., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102961 · Cited by 65
Faden, D. L., Ding, F., Lin, Y., Zhai, S., Kuo, F., Chan, T. A.-T., Morris, L. G. T., & Ferris, R. L. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.07.020 · Cited by 63
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 64
Rossi, G., Russo, A., Tagliamento, M., Tuzi, A., Nigro, O., Vallome, G., Sini, C., Grassi, M., Bello, M. G. D., Coco, S., et al. (2020) · Cancers · doi:10.3390/cancers12051125 · Cited by 68
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
Fröhlich, A., Sirokay, J. D., Fietz, S., Vogt, T. J., Dietrich, J., Zarbl, R., Florin, M., Kuster, P., Saavedra, G., Valladolid, S. R., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102962 · Cited by 62
Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry
Martínez-Morilla, S., Villarroel‐Espíndola, F., Wong, P. F., Toki, M. I., Aung, T. N., Pelekanou, V., Bourke-Martin, B., Schalper, K. A., Kluger, H. M., & Rimm, D. L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3340 · Cited by 65
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing
Lemoine, J., Ruella, M., & Houot, R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1559 · Cited by 67
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Filipović, A., Miller, G., & Bolen, J. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00155 · Cited by 63
“RNA was acquired at baseline from patients that went on to receive pembrolizumab and IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance appeared highly expressed in ultimate responders (Ayers et al., 2017).”
MethodBiomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
Isaacs, J. M., Anders, C. K., McArthur, H. L., & Force, J. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00833-4 · Cited by 64
Bertucci, F., Boudin, L., Finetti, P., Berckelaer, C. V., van Dam, P. A., Dirix, L. Y., Viens, P., Gonçalvès, A., Ueno, N. T., Laere, S. V., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929724 · Cited by 64
Liu, Z., Lu, T., Li, J., Wang, L., Xu, K., Dang, Q., Liu, L., Guo, C., Jiao, D., Sun, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702594 · Cited by 74
“The signature was composed of 18 inflammatory genes associated with antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance (33).”
BackgroundNKG7 Is Required for Optimal Antitumor T-cell Immunity
Li, X.-Y., Corvino, D., Nowlan, B., Aguilera, A. R., Ng, S. S., Braun, M., Cillo, A. R., Bald, T., Smyth, M. J., & Engwerda, C. R. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0649 · Cited by 63
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β
Olivera, I., Pamplona, R. S., Bolaños, E., Rodríguez, I., Etxeberría, I., Cirella, A., Egea, J., Garasa, S., Miguéliz, I., Eguren‐Santamaría, I., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1115 · Cited by 66
Sievers, C. M., Craveiro, M., Friedman, J., Robbins, Y. L., Yang, X., Bai, K., Nguyen, A., Redman, J. M., Chari, R., Soon‐Shiong, P., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.014 · Cited by 65
Arango-Argoty, G., Bikiel, D. E., Sun, G. J., Kipkogei, E., Smith, K. M., Pro, S. C., Choe, E. Y., & Jacob, E. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.029 · Cited by 67
Weed, D. T., Zilio, S., dos Reis, I. M., Sargi, Z., Abouyared, M., Gomez-Fernandez, C. R., Civantos, F., Rodriguez, C. P., & Serafini, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01206 · Cited by 61
Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy
Dai, Y.-H., Wang, Y.-F., Shen, P., Lo, C., Yang, J.-F., Lin, C., Chao, H., & Huang, W. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00200-0 · Cited by 64
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
Apriamashvili, G., Vredevoogd, D. W., Krijgsman, O., Bleijerveld, O. B., Ligtenberg, M. A., de Bruijn, B., Boshuizen, J., Traets, J. J. H., Altimari, D. M. D., Vliet, A. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29442-x · Cited by 63
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 61
Damrauer, J. S., Beckabir, W., Klomp, J. A., Zhou, M., Plimack, E. R., Galsky, M. D., Grivas, P. D., Hahn, N. M., O’Donnell, P. H., Iyer, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33980-9 · Cited by 64
VISTA expression and patient selection for immune-based anticancer therapy
Martin, A. S., Molloy, M., Ugolkov, A. V., Roemeling, R. W. V., Noelle, R. J., Lewis, L. D., Johnson, M. L., Radvanyi, L. G., & Martell, R. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1086102 · Cited by 64
Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Toker, J. S., Iorgulescu, J. B., Ling, A. L., Villa, G. R., Gadet, J. A. M. A., Parida, L., Getz, G. A., Wu, C. J., Reardon, D. A., Chiocca, E. A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3714 · Cited by 66
Xie, M., Vuko, M., Rodriguez‐Canales, J., Zimmermann, J., Schick, M., O’Brien, C., Paz-Ares, L. G., Goldman, J. W., Garassino, M. C., Gay, C. M., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02014-x · Cited by 71
Li, F., Yang, Z., Savage, T. M., Vincent, R. L., Santos, K. D. L., Ahn, A., Rouanne, M., Mariuzza, D. L., Danino, T., & Arpaia, N. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn9879 · Cited by 64
Bedognetti, D., Roelands, J. P., Decock, J. V., Wang, E., & Hendrickx, W. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170142 · Cited by 61
Melo, A. M., O’Brien, A., Phelan, J. J., Kennedy, S. A., Wood, N., Veerapen, N., Besra, G. S., Clarke, N. E., Foley, E. K., Ravi, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01580 · Cited by 63
Dölen, Y., Valente, M., Tagit, O., Jäger, E., van Dinther, E. A. W., van Riessen, N. K., Hrubý, M., Gileadi, U., Cerundolo, V., & Figdor, C. G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1738813 · Cited by 59
Biomarkers for immunotherapy for treatment of glioblastoma
Lynes, J. P., Nwankwo, A., Sur, H. P., Sanchez, V. E., Sarpong, K., Ariyo, O., Dominah, G. A., & Nduom, E. K.-E. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000348 · Cited by 63
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers
Bañobre, J. R., & Goel, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.071 · Cited by 62
The Current Landscape of Clinical Trials for Systemic Treatment of HCC
Foerster, F., & Galle, P. R. (2021) · Cancers · doi:10.3390/cancers13081962 · Cited by 59
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Zhao, X., Bao, Y., Meng, B., Xu, Z., Li, S., Wang, X., Hou, R., Ma, W., Liu, D., Zheng, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920021 · Cited by 67
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Li, B., Chen, H., Yang, S., Chen, F., Xu, L., Li, Y., Li, M., Zhu, C., Shao, F., Zhang, X., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01770-6 · Cited by 69
Lim, W., Kao, H., Suteja, L., Li, C. H., Quah, H. S., Tan, D. S. W., Tan, S. H., Tan, E.-H., Tan, W.-L., Lee, J. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38407-7 · Cited by 61
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
Rodrigues, M. J., Vanoni, G., Loap, P., Dubot, C., Timperi, E., Minsat, M., Bazire, L., Durdux, C., Fourchotte, V., Laas, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39383-8 · Cited by 66
An, M., Mehta, A., Min, B., Heo, Y. J., Wright, S. J., Parikh, M., Bi, L., Lee, H., Kim, T. J., Lee, S.-Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0857 · Cited by 67
McFaline-Figueroa, J. R., Sun, L., Youssef, G., Huang, R. Y., Li, G., Kim, J., Lee, E. Q., Nayak, L., Chukwueke, U. N., Beroukhim, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54326-7 · Cited by 70
Allen, C. T., Lee, S., Norberg, S. M., Kovalovsky, D., Hong, Y., Clavijo, P. E., Hu‐Lieskovan, S., Schlegel, R., Schlom, J., Strauss, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0603-3 · Cited by 59
Considering adjuvant therapy for stage II melanoma
Poklepovic, A. S., & Luke, J. J. (2019) · Cancer · doi:10.1002/cncr.32585 · Cited by 62
Comprehensive Immune Profiling of Medullary Thyroid Cancer
Pozdeyev, N. V., Erickson, T. A., Zhang, L., Ellison, K. E., Rivard, C. J., Sams, S. B., Hirsch, F. R., Haugen, B. R., & French, J. D. (2020) · Thyroid · doi:10.1089/thy.2019.0604 · Cited by 61
Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade
Wang, L., Gao, Y., Zhang, G., Li, D., Wang, Z., Zhang, J., Hermida, L. C., He, L., Wang, Z., Si, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2282 · Cited by 61
Gene expression profiles of breast cancer metastasis according to organ site
Brasó‐Maristany, F., Paré, L., Chic, N., Martínez‐Sáez, O., Pascual, T., Mallafré‐Larrosa, M., Schettini, F., González‐Farré, B., Sanfeliu, E., Martínez, D., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13021 · Cited by 66
Liu, S., Knochelmann, H. M., Lomeli, S. H., Hong, A., Richardson, M. S., Yang, Z., Lim, R. J., Wang, Y., Dumitras, C., Krysan, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100411 · Cited by 66
Molecular subtyping reveals immune alterations in IDH wild‐type lower‐grade diffuse glioma
Wu, F., Li, G., Liu, H., Zhao, Z., Chai, R., Liu, Y., Jiang, H., Zhai, Y., Feng, Y., Li, R., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5468 · Cited by 57
Tovo, P.-A., Garazzino, S., Daprà, V., Pruccoli, G., Calvi, C., Mignone, F., Alliaudi, C., Denina, M., Scolfaro, C., Zoppo, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147481 · Cited by 59
Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 60
Chand, D. S., Savitsky, D. A., Krishnan, S., Mednick, G., Delepine, C., García‐Broncano, P., Soh, K. T., Wu, W., Wilkens, M. K., Udartseva, O. O., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0190 · Cited by 63
Canton, D. A., Shirley, S. A., Wright, J. H., Connolly, R. J., Burkart, C., Mukhopadhyay, A., Twitty, C., Qattan, K. E., Campbell, J. S., Le, M. H., et al. (2017) · Immunotherapy · doi:10.2217/imt-2017-0096 · Cited by 60
Pro-inflammatory Cytokines Alter the Immunopeptidome Landscape by Modulation of HLA-B Expression
Javitt, A., Barnea, E., Kramer, M. P., Wolf-Levy, H., Levin, Y., Admon, A., & Merbl, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00141 · Cited by 59
Breast cancer vaccines: Heeding the lessons of the past to guide a path forward
Solinas, C., Aiello, M. M., Migliori, E., Willard-Gallo, K. E., & Emens, L. A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101947 · Cited by 57
“…vaccine trials are thought to be linked to: (1) patient selection factors (disease burden, extent of prior therapy, and tumor immune contexture) [20,21]; (2) the selection of TAAs to target; (3) the low immunogenicity of the vaccine as a result of the Ag chosen, or due to the vaccine delivery…”
BackgroundPhase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
Herbst, R. S., Arkenau, H., Bendell, J. C., Arrowsmith, E. R., Wermke, M., Soriano, A., Penel, N., Santana-Dávila, R., Bischoff, H. G., Chau, I., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.004 · Cited by 60
Ni, Y., Soliman, A., Joehlin-Price, A., Rose, P. G., Vlad, A., Edwards, R. P., & Mahdi, H. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00242-8 · Cited by 55
Wang, K., Patkar, S., Lee, J. S., Gertz, E. M., Robinson, W., Schischlik, F., Crawford, D. R., Schäffer, A. A., & Ruppin, E. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0887 · Cited by 55
Hilke, F. J., Sinnberg, T. W., Gschwind, A., Niessner, H., Demidov, G. M., Amaral, T. M. S., Ossowski, S., Bonzheim, I., Röcken, M., Rieß, O., et al. (2020) · Cancers · doi:10.3390/cancers12092359 · Cited by 73
Lechner, M. G., Patel, A. Y., Hugo, W., Angell, T. E., Cheng, M. I., Pioso, M. S., Hoang, A. T., Yakobian, N., McCarthy, E. C., Chen, H.-C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200244 · Cited by 58
Self-citationTargeting CXCL9/10/11–CXCR3 axis: an important component of tumor-promoting and antitumor immunity
Pan, M., Wei, X., Xiang, X., Liu, Y., Zhou, Q., & Yang, W.-B. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03126-4 · Cited by 63
Javitt, A., Shmueli, M. D., Kramer, M. P., Kolodziejczyk, A. A., Cohen, I., Radomir, L., Sheban, D., Kamer, I., Litchfield, K., Bab-Dinitz, E., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00557-4 · Cited by 59
Saeed, A., Park, R., Pathak, H. B., Al-Bzour, A. N., Dai, J., Phadnis, M. A., Al-Rajabi, R. M. T., Kasi, A., Baranda, J. C., Sun, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45960-2 · Cited by 60
Rodríguez‐Baena, F. J., Márquez-Galera, Á., Ballesteros-Martinez, P., Castillo, A., Diaz, E., Moreno‐Bueno, G., López‐Atalaya, J. P., & Sánchez‐Laorden, B. L. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.008 · Cited by 61
Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy
Gong, L., Luo, J., Yang, E., Ru, B., Qi, Z., Yang, Y., Rani, A., Purohit, A., Zhang, Y., Guan, G., et al. (2025) · Cell · doi:10.1016/j.cell.2025.07.004 · Cited by 59
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
García-Martínez, E., Smith, M. M., Buqué, A., Aranda, F., de la Peña, F. A., Rubio, A. I., Cánovas, M. S., Conesa, M. A. V., Fucikova, J. P., Špíšek, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433982 · Cited by 58
Boothman, A.-M., Scott, M. L. J., Ratcliffe, M., Whiteley, J. L., Dennis, P. A., Wadsworth, C., Sharpe, A. D., Rizvi, N. A., Garassino, M. C., & Walker, J. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.025 · Cited by 56
Christie, J. R., Lang, P., Zelko, L. M., Palma, D. A., Abdelrazek, M., & Mattonen, S. A. (2020) · Canadian Association of Radiologists Journal · doi:10.1177/0846537120941434 · Cited by 62
Wiesweg, M., Mairinger, F. D., Reis, H., Goetz, M., Kollmeier, J., Misch, D., Stephan-Falkenau, S., Mairinger, T., Walter, R. F. H., Hager, T., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.015 · Cited by 60
Sarshekeh, A. M., Alshenaifi, J. Y., Roszik, J., Manyam, G. C., Advani, S., Katkhuda, R., Verma, A., Lam, M. S., Willis, J. A., Shen, J. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2404 · Cited by 60
Kikuchi, T., Mimura, K., Okayama, H., Nakayama, Y., Saito, K., Yamada, L., Endo, E., Sakamoto, W., Fujita, S., Endo, H., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10953 · Cited by 65
Manzano, R. G., Catalán-Latorre, A., & Brugarolas, A. (2021) · BMC Cancer · doi:10.1186/s12885-021-08078-y · Cited by 61
“cytotoxic lymphocytes and NK cells, probably the most interesting and powerful effectors of the immunological response, and higher T cell inflamed signature scores, which have been related to interferon gamma responsive genes and to response to ICIs [16, 17].”
BackgroundMethodLong, J., Wang, D., Wang, A., Chen, P., Lin, Y. S., Bian, J., Yang, X., Zheng, M., Zhang, H., Zheng, Y., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01024-y · Cited by 63
Loi, S., Salgado, R., Schmid, P., Cortés, J., Cescon, D. W., Winer, E. P., Toppmeyer, D., Rugo, H. S., Laurentiis, M. D., Nanda, R., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00317 · Cited by 65
Self-citationGeurts, V. C. M., Balduzzi, S., Steenbruggen, T. G., Linn, S. C., Siesling, S., Badve, S., DeMichele, A. M., Ignatiadis, M., Leon-Ferre, R. A., Goetz, M. P., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1917 · Cited by 61
Levine, A., Nobre, L. F., Das, A., Milos, S., Bianchi, V., Johnson, M., Fernandez, N. R., Stengs, L. K., Ryall, S. T., Ku, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49595-1 · Cited by 57
Cheng, J., Jin, Z., Su, C., Jiang, T., Zheng, X., Guo, J., Li, X., Chu, H., Jia, J., Zhou, Q., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.036 · Cited by 63
Self-citationProgrammed death ligand‐1 expression as immunotherapeutic target in sinonasal cancer
Riobello, C., Vivanco, B., Reda, S., López‐Hernández, A., García–Inclán, C., Potes‐Ares, S., Cabal, V. N., López, F., Llorente, J. L., & Hermsen, M. A. J. A. (2018) · Head & Neck · doi:10.1002/hed.25067 · Cited by 56
Lee, J. J., & Chu, E. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.06.004 · Cited by 58
Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
Harryvan, T. J., Verdegaal, E. M. E., Hardwick, J. C. H., Hawinkels, L. J. A. C., & van der Burg, S. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111989 · Cited by 57
“Finally, the immune inflamed phenotype is also associated with better responsiveness to current immunotherapeutic interventions [63,64].”
BackgroundPredictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Sundar, R., Smyth, E. C., Peng, S., Yeong, J. P.-S., & Tan, P. B. O. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00763 · Cited by 57
Effern, M., Glodde, N., Braun, M., Liebing, J., Boll, H. N., Yong, M. C. R., Bawden, E., Hinze, D., Konijnenberg, D., Daoud, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.007 · Cited by 58
Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway
Chai, A. W. Y., Yee, P. S., Price, S., Yee, S. M., Lee, H. M., Tiong, V. K., Gonçalves, E., Behan, F. M., Bateson, J., Gilbert, J. G. R., et al. (2020) · eLife · doi:10.7554/elife.57761 · Cited by 58
Grasso, C. S., Tsoi, J., Onyshchenko, M. I., Abril-Rodríguez, G., Ross‐Macdonald, P., Wind‐Rotolo, M., Champhekar, A. S., Medina, E., Torrejon, D. Y., Shin, D. S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.11.015 · Cited by 62
Self-citationLi, S., Wu, X., Yan, X., Zhou, L., Chi, Z., Si, L., Cui, C., Tang, B., Mao, L., Lian, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004036 · Cited by 59
Bellmunt, J., de Wit, R., Fradet, Y., Climent, M. A., Petrylak, D. P., Lee, J.-L., Fong, L. H., Necchi, A., Sternberg, C. N., O'Donnell, P. H., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3089 · Cited by 60
Self-citationBoukhaled, G. M., Gadalla, R., Elsaesser, H. J., Abd-Rabbo, D., Quevedo, R., Yang, S. Y. C., Guo, M., Wang, B. X., Noamani, B., Gray, D., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01262-7 · Cited by 59
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
Ghatalia, P., Zibelman, M. R., Geynisman, D. M., & Plimack, E. R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918788310 · Cited by 58
Liu, Z., Liu, J., Liu, X., Wang, X., Xie, Q., Zhang, X., Kong, X., He, M., Yang, Y., Deng, X., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab860 · Cited by 73
“Previous studies have proved that patient-derived clinical transcriptomes with therapy response can help reveal drug resistance mechanism (3,4), and baseline (i.e. pre-treatment) transcriptomic signals of patients are promising biomarker candidates for predicting drug response (5,6).”
Pagadala, M. S., Sears, T. J., Wu, V. H., Pérez‐Guijarro, E., Kim, H., Castro, A., Talwar, J. V., González-Colín, C., Cao, S., Schmiedel, B. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38271-5 · Cited by 66
He, S., Wang, L., Wu, D., Tong, F., Zhao, H., Li, H., Gong, T., Gao, H., & Zhou, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.10.006 · Cited by 59
Kato, R., Yamasaki, M., Urakawa, S., Nishida, K., Makino, T., Morimoto-Okazawa, A., Kawashima, A., Iwahori, K., Suzuki, S., Ueda, R., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2225-x · Cited by 56
Malissen, N., Macagno, N., Granjeaud, S., Granier, C., Moutardier, V., Gaudy‐Marqueste, C., Habel, N., Mandavit, M., Guillot, B., Pasero, C., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1665976 · Cited by 59
“Cohort 116 65 (56) 51 (44) Men 65 31 (48) 34 (52) Women 51 34 (67) 17 (33) Median age at initial diagnostic [range] 56 [19-89] 54 [25-86]”
Immune profiling of pediatric solid tumors
Terry, R. L., Meyran, D., Ziegler, D. S., Haber, M., Ekert, P. G., Trapani, J. A., & Neeson, P. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137181 · Cited by 56
Metadata
- Authors
- Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., Piha-Paul, S. A., Yearley, J., Seiwert, T. Y., Ribas, A., & McClanahan, T. K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Washington (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- McClanahan, Terrill K.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-06-26
- Volume
- 127
- Issue
- 8
- Pages
- 2930-2940
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531419
- OpenAlex
- W2655262992
- Cited by
- 3,788
- References
- 31
- Citations by year
- 2026: 358 · 2025: 391 · 2024: 518 · 2023: 551 · 2022: 608 · 2021: 512 · 2020: 400 · 2019: 263 · 2018: 159 · 2017: 24
- FWCI
- 101.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- interferon-gamma, anti-PD-1 therapy, pembrolizumab, predictive biomarkers, gene expression profiles, PD-L1 expression, immune checkpoint inhibitors, melanoma, head and neck squamous cell carcinoma, adaptive immune resistance, antigen presentation, chemokine expression
- MeSH terms
- Antineoplastic Agents, Biopsy, Carcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Immune System, Immunohistochemistry, Interferon-gamma, Lung Neoplasms, Melanoma, Pilot Projects, ROC Curve, Skin Neoplasms, Stomach Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Sequence Analysis, RNA, Gene Expression Profiling, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.